Exceeded Enrollment Goal Timelines and Reduced Study Spending
Case Study
Mar 20, 2020
Patient recruitment services fulfilled actinic keratosis (AK) enrollment goals up to 75% faster than sponsor-projected timelines and significantly reduced overall study spending
Failure of sites to fulfill enrollment expectations on time often leads to major delays in clinical development programs. IQVIA Biotech was selected to conduct multiple large Phase III actinic keratosis studies, which involved from 60-960 patients in various sites in the United States. Our patient recruitment services fulfilled enrollment goals up to 75% faster than sponsor-projected timelines and significantly reduced overall study spending. As a result, IQVIA Biotech was instrumental in assisting these sponsors with moving forward efficiently with their overall clinical development plans.